Your browser doesn't support javascript.
loading
Prevalence and Factors Associated With Patient-Clinician Discordance Among Patients With Rheumatoid Arthritis Initiating Advanced Therapy.
Curtis, Jeffrey R; McLean, Robert R; Lee, I-Heng; Mackey, Rachel H; Moore, Page C; Haubrich, Richard; Greenberg, Jeffrey D; Wu, Alicea.
Afiliação
  • Curtis JR; University of Alabama at Birmingham.
  • McLean RR; CorEvitas, LLC, Waltham, Massachusetts.
  • Lee IH; Gilead Sciences, Inc., Foster City, California.
  • Mackey RH; CorEvitas, LLC, Waltham, Massachusetts, and University of Pittsburgh, Pittsburg, Pennsylvania.
  • Moore PC; CorEvitas, LLC, Waltham, Massachusetts.
  • Haubrich R; Gilead Sciences, Inc., Foster City, California.
  • Greenberg JD; CorEvitas, LLC, Waltham, Massachusetts, and New York University School of Medicine, New York.
  • Wu A; Gilead Sciences, Inc., Foster City, California.
ACR Open Rheumatol ; 6(5): 253-264, 2024 May.
Article em En | MEDLINE | ID: mdl-38429905
ABSTRACT

OBJECTIVE:

To describe and identify associated factors for patient-clinician discordance of disease assessment at biologic or Janus kinase inhibitor (JAKi) initiation and over 12 months following initiation in patients with rheumatoid arthritis (RA) from a US RA registry.

METHODS:

Analyses included CorEvitas RA Registry patients who initiated their first biologic or JAKi on or after February 1, 2015, and had 6- and 12-month follow-up visits. Positive discordance was defined as patient global assessment (visual analog scale [VAS-100]) minus physician's global assessment (VAS-100) equal to 30 points or more. Persistent discordance was defined as positive discordance at all three visits. Mixed-effects logistic regression was used to determine risk factors for positive discordance at initiation and for persistent discordance.

RESULTS:

Among 2227 first-time biologic/JAKi-initiating patients, 613 had both follow-up visits available and were included in initiation visit analyses, and of these, 163 had positive discordance at initiation and were included in persistent discordance analyses. About 30% of all patients had positive discordance at any visit, and one third of these (10% total) were persistent at all three visits. Multivariable analyses revealed that worse scores on the Clinical Disease Activity Index, greater patient-reported pain and fatigue, and greater functional impairment were associated with positive discordance at the time of therapy initiation. Being disabled versus working full-time and being female were associated with higher odds and having Medicare versus no insurance was associated with lower odds of having persistent positive discordance.

CONCLUSION:

Results suggest positive discordance is common among real-world patients with RA initiating their first biologic or JAKi. The identified risk factors associated with patient-clinician discordance will help clinicians foster a more patient-centric discussion in treatment decisions.

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article